A transferrin-modified liposome (AA@Tf-Lip) was constructed for co-delivery, and antitumor efficacy evaluated <i>in vitro</i> and <i>in vivo</i>.<h4>Results</h4>High RDM1 expression predicted poor HCC survival. Here, TF is linked to hepatocellular carcinoma.